Literature DB >> 2538549

Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.

C F Perno1, R Yarchoan, D A Cooney, N R Hartman, D S Webb, Z Hao, H Mitsuya, D G Johns, S Broder.   

Abstract

We have investigated the influence of granulocyte-macrophage CSF (GM-CSF) on the replication of HIV-1 in cells of monocyte/macrophage (M/M) lineage, and its effect on the anti-HIV activity of several 2'3'-dideoxynucleoside congeners of thymidine in these cells in vitro. We found that replication of both HTLV-IIIBa-L (a monocytotropic strain of HIV-1) and HTLV-IIIB (a lymphocytotropic strain) is markedly enhanced in M/M, but not in lymphocytes exposed to GM-CSF in culture. Moreover, GM-CSF reduced the dose of HIV required to obtain productive infection in M/M. Even in the face of this increased infection, GM-CSF also enhanced the net anti-HIV activity of 3'-azido-2'3'-dideoxythymidine (AZT) and several related congeners: 2'3'-dideoxythymidine (ddT), 2'3'-dideoxy-2'3'-didehydrothymidine (D4T), and 3'-azido-2'3'-dideoxyuridine (AZddU). Inhibition of viral replication in GM-CSF-exposed M/M was achieved with concentrations of AZT and related drugs, which were 10-100 times lower than those inhibitory for HIV-1 in monocytes in the absence of GM-CSF. Other dideoxynucleosides not related to AZT showed unchanged or decreased anti-HIV activity in GM-CSF-exposed M/M. To investigate the possible biochemical basis for these effects, we evaluated the metabolism of several drugs in M/M exposed to GM-CSF. We observed in these cells markedly increased levels of both parent and mono-, di-, and triphosphate anabolites of AZT and D4T compared with M/M not exposed to GM-CSF. By contrast, only limited increases of endogenous competing 2'-deoxynucleoside-5'-triphosphate pools were observed after GM-CSF exposure. Thus, the ratio of AZT-5'-triphosphate/2'-deoxythymidine-5'-triphosphate and 2'3'-dideoxy-2'3'-didehydrothymidine-5'-triphosphate/2'-deoxythymi dine- 5'-triphosphate is several-fold higher in GM-CSF-exposed M/M, and this may account for the enhanced activity of such drugs in these cells. Taken together, these findings suggest that GM-CSF increases HIV-1 replication in M/M, while at the same time enhancing the anti-HIV activity of AZT and related congeners in these cells. These results may have implications in exploring new therapeutic strategies in patients with severe HIV infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538549      PMCID: PMC2189284          DOI: 10.1084/jem.169.3.933

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  40 in total

1.  Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; G Ahluwalia; H Mitsuya; A Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

Review 2.  The human hematopoietic colony-stimulating factors.

Authors:  S C Clark; R Kamen
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

3.  Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation.

Authors:  B Thorens; J J Mermod; P Vassalli
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

4.  Expression of the M-CSF (CSF-1) gene by human monocytes.

Authors:  A Rambaldi; D C Young; J D Griffin
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

5.  3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion.

Authors:  T P Zimmerman; W B Mahony; K L Prus
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

6.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

Authors:  R Yarchoan; G Berg; P Brouwers; M A Fischl; A R Spitzer; A Wichman; J Grafman; R V Thomas; B Safai; A Brunetti
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

9.  In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon.

Authors:  S M Hammer; J M Gillis; J E Groopman; R M Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.

Authors:  C F Perno; R Yarchoan; D A Cooney; N R Hartman; S Gartner; M Popovic; Z Hao; T L Gerrard; Y A Wilson; D G Johns
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  50 in total

Review 1.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 4.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Inhibition of human immunodeficiency virus replication in a human T cell line by antisense RNA expressed in the cell.

Authors:  J Gyotoku; M A el-Farrash; S Fujimoto; W T Germeraad; Y Watanabe; K Teshigawara; S Harada; Y Katsura
Journal:  Virus Genes       Date:  1991-07       Impact factor: 2.332

6.  The influence of macrophage growth factors on Theiler's Murine Encephalomyelitis Virus (TMEV) infection and activation of macrophages.

Authors:  Karin M Schneider; Neva B Watson; Scott B Minchenberg; Paul T Massa
Journal:  Cytokine       Date:  2017-08-09       Impact factor: 3.861

7.  Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team.

Authors:  D Hardy; S Spector; B Polsky; C Crumpacker; C van der Horst; G Holland; W Freeman; M H Heinemann; G Sharuk; J Klystra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

8.  Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor.

Authors:  F D Davison; R S Kaczmarski; A Pozniak; G J Mufti; S Sutherland
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

9.  Successful treatment of Cisplatin overdose with plasma exchange.

Authors:  Yasuhiro Yamada; Yoshiaki Ikuta; Kisato Nosaka; Nobutomo Miyanari; Naoko Hayashi; Hiroaki Mitsuya; Hideo Baba
Journal:  Case Rep Med       Date:  2010-03-11

10.  Cytokine influence on simian immunodeficiency virus replication within primary macrophages. TNF-alpha, but not GMCSF, enhances viral replication on a per-cell basis.

Authors:  D G Walsh; C J Horvath; A Hansen-Moosa; J J MacKey; P K Sehgal; M D Daniel; R C Desrosiers; D J Ringler
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.